Product Description
MET Antibody [F8D4] | 13-495 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: Recombinant protein of human MET
Research Area: Cancer, Cell Cycle, Growth Factors, Signal Transduction, Stem Cell
Tested Application: WB, IHC, IF
Application: WB: 1:500 - 1:1000
IHC: 1:20 - 1:50
IF: 1:20 - 1:50
Specificiy: N/A
Positive Control 1: HepG2
Positive Control 2: SW620
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: Observed: 120kDa
Validation: N/A
Isoform: N/A
Purification: Affinity purification
Clonality: Monoclonal
Clone: [F8D4]
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.02% sodium azide, pH7.3.
Concentration: N/A
Storage Condition: Store at 4˚C. Avoid freeze / thaw cycles.
Alternate Name: MET, AUTS9, C-Met, HGF/SF receptor, HGFR, Met kinase, Proto-oncogene c-Met, Scatter factor receptor, SF receptor, HGF receptor, RCCP2, Tyrosine-protein kinase Met
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers.